Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Frewer

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|March 19, 2016
Decision-making in early clinical drug developmentPaul Frewer, Pat Mitchell, Claire Watkins, et al.
Therapeutic Innovation & Regulatory Science|January 6, 2022
Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in OncologyKristine Broglio, Jayne Marshall, Binbing Yu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 27, 2016
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor ReceptorPaul A Dickinson, Mireille V Cantarini, Jo Collier, et al.
Clinical Endocrinology|April 23, 2002
Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhoodAndrea F Attanasio, Simon Howell, Peter C Bates, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2002
Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patientsAndrea F Attanasio, Simon Howell, Peter C Bates, et al.
British Journal of Clinical Pharmacology|July 29, 2021
Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolamSong Ren, Karthick Vishwanathan, Mireille Cantarini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2017
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung CancersPaul K Paik, Ronglai Shen, Michael F Berger, et al.
The Journal of Clinical Endocrinology and Metabolism|May 8, 2002
Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithmsAnne Kehely, Peter C Bates, Paul Frewer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2005
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET studyWolfgang H Oertel, Erik Wolters, Cristina Sampaio, et al.
The Lancet. Oncology|February 7, 2020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|March 19, 2016
Decision-making in early clinical drug developmentPaul Frewer, Pat Mitchell, Claire Watkins, et al.
Therapeutic Innovation & Regulatory Science|January 6, 2022
Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in OncologyKristine Broglio, Jayne Marshall, Binbing Yu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 27, 2016
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor ReceptorPaul A Dickinson, Mireille V Cantarini, Jo Collier, et al.
Clinical Endocrinology|April 23, 2002
Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhoodAndrea F Attanasio, Simon Howell, Peter C Bates, et al.
The Journal of Clinical Endocrinology and Metabolism|July 11, 2002
Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patientsAndrea F Attanasio, Simon Howell, Peter C Bates, et al.
British Journal of Clinical Pharmacology|July 29, 2021
Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolamSong Ren, Karthick Vishwanathan, Mireille Cantarini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2017
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung CancersPaul K Paik, Ronglai Shen, Michael F Berger, et al.
The Journal of Clinical Endocrinology and Metabolism|May 8, 2002
Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithmsAnne Kehely, Peter C Bates, Paul Frewer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2005
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET studyWolfgang H Oertel, Erik Wolters, Cristina Sampaio, et al.
The Lancet. Oncology|February 7, 2020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.
Pageof 2